Sentry Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Sentry Investment Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-123	Closed	-$44K	–	464
2023 Q3	$44K	Sell	123 -17	-12%	-$6.56K	0.02%	479
2023 Q2	$53K	Hold	140	–	–	0.02%	477
2023 Q1	$67K	Sell	140 -8	-5%	-$3.75K	0.03%	430
2022 Q4	$62K	Hold	148	–	–	0.03%	433
2022 Q3	$62K	Hold	148	–	–	0.03%	442
2022 Q2	$73K	Buy	148 +21	+17%	+$10.9K	0.03%	431
2022 Q1	$72K	Sell	127 -72	-36%	-$43.4K	0.02%	467
2021 Q4	$150K	Buy	199 +48	+32%	+$35.9K	0.04%	375
2021 Q3	$113K	Sell	151 -22	-13%	-$16.5K	0.03%	417
2021 Q2	$111K	Hold	173	–	–	0.03%	408
2021 Q1	$99K	Sell	173 -1,159	-87%	-$686K	0.03%	431
2020 Q4	$776K	Hold	1,332	–	–	0.04%	356
2020 Q3	$687K	Sell	1,332 -461	-26%	-$233K	0.04%	331
2020 Q2	$810K	Buy	+1,793	New	+$791K	0.05%	327

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sentry Investment Management's BIO Position: Q4 2023 in Review

Sentry Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 123 shares — an estimated $44K sold.

Sentry Investment Management first reported a position in BIO in Q2 2020 and held it in 14 quarters. The position peaked at $810K in Q2 2020. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

Sentry Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
Sentry Investment Management sold 123 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $44K.
Sentry Investment Management first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 14 quarters.
Sentry Investment Management's Bio-Rad Laboratories Class A position peaked at $810K in Q2 2020.
484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Sentry Investment Management's 13F filing for Q4 2023, filed 30 Jan 2024.